Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,042 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,672 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03241537 | COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer | active not recruiting | Phase 3 | 61 | Samsung Medical CenterOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT03319628 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | active not recruiting | Phase 1 / Phase 2 | 523 | Mersana TherapeuticsINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT04152512 |
| Quality of Life, Unmet Needs and Satisfaction With Care After Vulvar Cancer(PROVE) |
| active not recruiting |
| — |
| 153 |
| Karolinska University HospitalOTHER |
| 1 |
| Nov 1, 2023 |
| clinicaltrials |
| NCT03469674 | PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer(PORTEC-4a) | active not recruiting | Phase 3 | 550 | Leiden University Medical CenterOTHER | 8 | Oct 11, 2023 | clinicaltrials |
| NCT04299620 | Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy | active not recruiting | N/A | 86 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT02881242 | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | active not recruiting | Phase 2 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT03381105 | From PSA to Stockholm3: Study Part 1(PSA2STHLM3/1) | active not recruiting | — | 13,431 | Helse Stavanger HFOTHER_GOV | 1 | Apr 24, 2023 | clinicaltrials |
| NCT00268476 | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy(STAMPEDE) | active not recruiting | Phase 2 / Phase 3 | 11,992 | Medical Research CouncilOTHER_GOV | 2 | Apr 18, 2023 | clinicaltrials |
| NCT04138914 | Phase II Trial of Focal Cryotherapy for Prostate Cancer | active not recruiting | N/A | 30 | Singapore General HospitalOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03064087 | Validation of Human Papillomavirus Assays and Collection Devices for Self-samples and Urine Samples(VALHUDES) | active not recruiting | — | 500 | Marc ArbynOTHER_GOV | 1 | Mar 29, 2023 | clinicaltrials |
| NCT00430183 | Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer | active not recruiting | Phase 3 | 788 | Alliance for Clinical Trials in OncologyOTHER | 2 | Feb 9, 2023 | clinicaltrials |
| NCT02803086 | Longitudinal Evaluation of Intestinal, Haematological and Urinary Toxicity From Pelvic Irradiation for Prostate Cancer(IHU-WPRT-TOX) | active not recruiting | — | 700 | IRCCS San RaffaeleOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT00860652 | Radiotherapy - Adjuvant Versus Early Salvage(RAVES) | active not recruiting | N/A | 333 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Nov 18, 2022 | clinicaltrials |
| NCT02044172 | Prostate Testing for Cancer and Treatment(ProtecT) | active not recruiting | N/A | 82,849 | University of OxfordOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT03061539 | Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature | active not recruiting | Phase 2 | 380 | University College, LondonOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT01464216 | MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness(FuncProst) | active not recruiting | — | 120 | Oslo University HospitalOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02623933 | MRI Assisted Focal Boost With HDR Monotherapy for Prostate Cancer Patients(MARS) | active not recruiting | N/A | 60 | Sunnybrook Health Sciences CentreOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04024475 | Prostate Cancer Biobank | active not recruiting | — | 1,323 | Swiss Cancer InstituteOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT03585114 | Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers | active not recruiting | Phase 2 | 11 | Columbia UniversityOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT03824275 | 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer | active not recruiting | Phase 2 / Phase 3 | 129 | Columbia UniversityOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT03444844 | Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 60 | Five Eleven Pharma, Inc.INDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT03836352 | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | active not recruiting | Phase 2 | 184 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Mar 31, 2022 | clinicaltrials |
| NCT02243033 | Phase II Laser Focal Therapy of Prostate Cancer(LITT or FLA) | active not recruiting | — | 1,000 | HALO DiagnosticsINDUSTRY | 1 | Mar 25, 2022 | clinicaltrials |
| NCT04848545 | Endocrine Disrupting Chemical Exposure and Testicular Cancer(DISRUPT) | active not recruiting | — | 700 | Rigshospitalet, DenmarkOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT02487693 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma | active not recruiting | Phase 2 | 50 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
| NCT02490748 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer | active not recruiting | Phase 2 | 10 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Nov 27, 2023source: clinicaltrials